Trump administration officials blocked an FDA fast-track review of a psilocybin treatment for severe depression, Reuters reporting highlights internal discord

Psilocybin depression drug fast-track review was blocked when Trump administration officials vetoed an FDA plan to speed up review of a psychedelic treatment for severe depression. The FDA had put a Compass Pathways psilocybin treatment on a list of promising medicines meant for speedy regulatory review. When FDA Commissioner Marty Makary sought sign-off from the Health and Human Services Department and the White House in October, his superiors rejected the plan, according to people familiar with the process. The veto reportedly came just hours before the FDA announced Commissioner’s National Priority Vouchers, where Compass’ medicine was the only one not to make the final list. The decision is framed as suggesting possible internal discord between senior leadership and the Make America Healthy Again movement.